Arvinas, Inc. (NASDAQ:ARVN) Receives Consensus Rating of "Hold" from Brokerages

Key Points

• Arvinas now carries a consensus analyst rating of “Hold” from 15 brokerages, with 3 sell ratings, 3 hold ratings, and 9 buy ratings. The average 12-month price target is about $14.86.
• Recent analyst actions have been mixed, including downgrades from Zacks Research and Wall Street Zen, while Piper Sandler maintained an Overweight rating and raised its target to $20.
• The company reported a weak quarter, posting a loss of $1.10 per share versus expectations for a smaller loss and revenue of $9.5 million, far below estimates. Insiders also sold shares recently, including the CFO and CEO.

Shares of Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) have been given a consensus recommendation of "Hold" by the fifteen ratings firms that are currently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $14.8571.

A number of research analysts have recently weighed in on the company. Zacks Research cut Arvinas from a "hold" rating to a "strong sell" rating in a research report on Monday, April 27th. Truist Financial set a $10.00 price target on Arvinas in a research report on Wednesday, March 18th. Weiss Ratings restated a "sell (d-)" rating on shares of Arvinas in a research report on Friday, April 10th. Wall Street Zen cut Arvinas from a "hold" rating to a "sell" rating in a research report on Monday, March 2nd. Finally, Piper Sandler restated an "overweight" rating and issued a $20.00 price target (up from $16.00) on shares of Arvinas in a research report on Wednesday, February 25th.

Insiders Place Their Bets

In related news, CFO Andrew Saik sold 5,134 shares of Arvinas stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $11.89, for a total transaction of $61,043.26. Following the completion of the sale, the chief financial officer owned 159,267 shares in the company, valued at approximately $1,893,684.63. This trade represents a 3.12% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Randy Teel sold 4,786 shares of Arvinas stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $12.16, for a total value of $58,197.76. Following the sale, the chief executive officer owned 149,696 shares of the company's stock, valued at approximately $1,820,303.36. This represents a 3.10% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 63,864 shares of company stock valued at $802,443. Company insiders own 7.30% of the company's stock.

Institutional Trading of Arvinas

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. ProShare Advisors LLC increased its position in Arvinas by 7.2% during the 4th quarter. ProShare Advisors LLC now owns 14,827 shares of the company's stock worth $176,000 after purchasing an additional 993 shares in the last quarter. Intech Investment Management LLC increased its position in Arvinas by 3.6% during the 3rd quarter. Intech Investment Management LLC now owns 32,653 shares of the company's stock worth $278,000 after purchasing an additional 1,125 shares in the last quarter. MetLife Investment Management LLC increased its position in Arvinas by 4.3% during the 4th quarter. MetLife Investment Management LLC now owns 33,810 shares of the company's stock worth $401,000 after purchasing an additional 1,381 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Arvinas by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,636 shares of the company's stock worth $271,000 after purchasing an additional 2,122 shares in the last quarter. Finally, Oxford Asset Management LLP increased its position in Arvinas by 15.5% during the 2nd quarter. Oxford Asset Management LLP now owns 16,705 shares of the company's stock worth $123,000 after purchasing an additional 2,242 shares in the last quarter. Hedge funds and other institutional investors own 95.19% of the company's stock.

Arvinas Stock Performance

NASDAQ:ARVN opened at $10.11 on Monday. The stock has a fifty day moving average price of $11.43 and a two-hundred day moving average price of $11.68. The stock has a market capitalization of $652.30 million, a price-to-earnings ratio of -7.90 and a beta of 1.79. Arvinas has a 1 year low of $5.90 and a 1 year high of $14.51.

Arvinas (NASDAQ:ARVN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($1.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.55). Arvinas had a negative net margin of 30.77% and a negative return on equity of 14.25%. The firm had revenue of $9.50 million during the quarter, compared to analysts' expectations of $37.26 million. During the same quarter in the prior year, the business earned ($0.63) EPS. The company's quarterly revenue was down 84.0% compared to the same quarter last year. On average, analysts predict that Arvinas will post -3.25 EPS for the current year.

Arvinas Company Profile

Arvinas, Inc NASDAQ: ARVN is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body's natural protein-recycling systems.

The company's most advanced clinical candidates address hormone-driven cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.